<H1>Chapter DOI: 10.1208/aapsj070479<br/>Cited-By Count: 39</H1><table border="1" width="30%"><tr><td>Total References</td><td>104</td></tr><tr><td>Springer references</td><td>12</td></tr><tr><td>Non Springer references</td><td>92</td></tr><tr><td>BibStructured Count</td><td width="10%">99</td></tr><tr><td>BibUnstructured Count</td><td width="10%">5</td></tr><tr><td>DOI already available in SpringerLink</td><td>56</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>17</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>2</td></tr><tr><td>DOI Obtained For Non Springer</td><td>15</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>16</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>1</td></tr><tr><td>Valid DOI Enriched</td><td>10</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Stewart PA, Tuor UI. Blood-eye barriers in the rat: correlation of ultrastructure with function.<Emphasis Type="Italic">J Comp Neurol</Emphasis>. 1994;340:566&#8211;576.</td><td><a href=http://dx.doi.org/10.1002/cne.903400409>10.1002/cne.903400409</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Schoenwald RD. Ocular drug delivery: pharmacokinetic considerations.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1990;18:255&#8211;269.</td><td><a href=http://dx.doi.org/10.2165/00003088-199018040-00001>10.2165/00003088-199018040-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1988;77:771&#8211;775.</td><td><a href=http://dx.doi.org/10.1002/jps.2600770911>10.1002/jps.2600770911</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Davies NM. Biopharmaceutical considerations in topical ocular drug delivery.<Emphasis Type="Italic">Clin Exp Pharmacol Physiol</Emphasis>. 2000;27:558&#8211;562.</td><td><a href=http://dx.doi.org/10.1046/j.1440-1681.2000.03288.x>10.1046/j.1440-1681.2000.03288.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Grass GM, Robinson JR. Mechanism of corneal penetration. I. In vivo and in vitro kinetics.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1988;77:3&#8211;14.</td><td><a href=http://dx.doi.org/10.1002/jps.2600770103>10.1002/jps.2600770103</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjuctiva: a literature analysis for drug delivery to the eye.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1998;87:1479&#8211;1488.</td><td><a href=http://dx.doi.org/10.1021/js9802594>10.1021/js9802594</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Edwards A, Prausnitz MR. Predicted permeability of the cornea to topical drugs.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2001;18:1497&#8211;1508.</td><td><a href=http://dx.doi.org/10.1023/A:1013061926851>10.1023/A:1013061926851</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges.<Emphasis Type="Italic">J Ocul Pharmacol</Emphasis>. 1986;2:67&#8211;108.</td><td><a href=http://dx.doi.org/10.1089/jop.1986.2.67>10.1089/jop.1986.2.67</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Sasaki H, Yamamura K, Mukai T, et al. Enhancement of ocular drug penetration.<Emphasis Type="Italic">Crit Rev Ther Drug Carrier Syst</Emphasis>. 1999;16:85&#8211;146.</td><td><a href=http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v16.i1.20>10.1615/CritRevTherDrugCarrierSyst.v16.i1.20</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, JournalTitle, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR10</td><td>BibBook</td><td>Bundgaard H, ed.<Emphasis Type="Italic">Design of Prodrugs</Emphasis>. Amsterdam, The Netherlands: Elsevier Science; 1985.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Bodor N, Kaminski JJ. Prodrugs and site-specific chemical delivery systems.<Emphasis Type="Italic">Annu Rep Med Chem</Emphasis>. 1987;22:303&#8211;313.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibChapter</td><td>Wermuth CG, Gaignault J-C, Marchandeau C. Designing prodrugs and bioprecursors I: Carrier prodrugs. In: Wermuth CG, ed.<Emphasis Type="Italic">The Practice of Medicinal Chemistry</Emphasis>. London, UK: Academic Press; 1996:671&#8211;696.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Ettmayer P, Amidon GL, Clement B, Testa B. Lessons learned from marketed and investigational prodrugs.<Emphasis Type="Italic">J Med Chem</Emphasis>. 2004;47:2393&#8211;2404.</td><td><a href=http://dx.doi.org/10.1021/jm0303812>10.1021/jm0303812</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Bodor N. Drug targeting and retrom etabolic drug design approaches.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 1994;14:157&#8211;166.</td><td><a href=http://dx.doi.org/10.1016/0169-409X(94)90036-1>10.1016/0169-409X(94)90036-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Bodor N. Buchwald P. Drug targeting via retrometabolic approaches.<Emphasis Type="Italic">Pharmacol Ther</Emphasis>. 1997;76:1&#8211;27.</td><td><a href=http://dx.doi.org/10.1016/S0163-7258(97)00098-3>10.1016/S0163-7258(97)00098-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibChapter</td><td>Bodor N, Buchwald P. Retrometabolism-based drug design and targeting. In: Abraham DJ, ed.<Emphasis Type="Italic">Drug Discovery and Drug Development. Burger&#8217;s Medicinal Chemistry and Drug Discovery</Emphasis>. Vol 2. 6th ed. New York, NY: John Wiley and Sons; 2003:533&#8211;608.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Bodor N, El-Koussi A, Kano M, Nakamuro T. Improved delivery through biological membranes. 26. Design, synthesis, and pharmacological activity of a novel chemical delivery system for &#946;-adrenergic blocking agents.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1988;31:100&#8211;106.</td><td><a href=http://dx.doi.org/10.1021/jm00396a015>10.1021/jm00396a015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>El-Koussi A, Bodor N. Formation of propanolol in the iris-ciliary body from its propranolol ketoxime precursor&#8212;a potential antiglaucoma drug.<Emphasis Type="Italic">Int J Pharm</Emphasis>. 1989;53:189&#8211;194.</td><td><a href=http://dx.doi.org/10.1016/0378-5173(89)90312-8>10.1016/0378-5173(89)90312-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Bodor N, Prokai L. Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1990;7:723&#8211;725.</td><td><a href=http://dx.doi.org/10.1023/A:1015863521513>10.1023/A:1015863521513</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Bodor N, El-Koussi A. Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime&#8212;a new potential antiglaucoma agent.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1991;8:1389&#8211;1395.</td><td><a href=http://dx.doi.org/10.1023/A:1015849123020>10.1023/A:1015849123020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Simay A, Prokai L, Bodor N. Oxidation of aryloxy-&#946;-amino alcohols with activated dimethylsulfoxide: a novel C-N oxidation facilitated by neighboring group effect.<Emphasis Type="Italic">Tetrahedron</Emphasis>. 1989;45:4091&#8211;4102.</td><td><a href=http://dx.doi.org/10.1016/S0040-4020(01)81305-3>10.1016/S0040-4020(01)81305-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibChapter</td><td>Simay A, Bodor N. Site- and stereospecific drug delivery to the eye. In: Sarel S, Mechoulam R, Agranat I, eds.<Emphasis Type="Italic">Trends in Medicinal Chemistry &#8217;90</Emphasis>. Oxford, UK: Blackwell Scientific Publications; 1992:361&#8211;368.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Bodor N. Retrometabolic drug design concepts in ophthalmic targetspecific drug delivery.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 1995;16:21&#8211;38.</td><td><a href=http://dx.doi.org/10.1016/0169-409X(95)00011-U>10.1016/0169-409X(95)00011-U</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Polgar P, Bodor N. Minimal cardiac electrophysiological activity of alprenoxime, a site-activated ocular &#946;-blocker, in dogs.<Emphasis Type="Italic">Life Sci</Emphasis>. 1995;56:1207&#8211;1213.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(95)00060-J>10.1016/0024-3205(95)00060-J</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Prokai L, Wu W-M, Somogyi G, Bodor N. Ocular delivery of the &#946;-adrenergic antagonist alprenolol by sequential bioactivation of its methoxime analog.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1995;38:2018&#8211;2020.</td><td><a href=http://dx.doi.org/10.1021/jm00011a021>10.1021/jm00011a021</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Bodor N, Farag HH, Somogyi G, Wu W-M, Barros MDC, Prokai L. Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs.<Emphasis Type="Italic">J Ocul Pharmacol</Emphasis>. 1997;13:389&#8211;403.</td><td><a href=http://dx.doi.org/10.1089/jop.1997.13.389>10.1089/jop.1997.13.389</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Farag HH, Wu W-M, Barros MDC, Somogyi G, Prokai L, Bodor N. Ocular-specific chemical delivery system of betaxolol for safe local treatment of glaucoma.<Emphasis Type="Italic">Drug Des Discov</Emphasis>. 1997;15:117&#8211;130.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Nathanson JA. Stereospecificity of beta adrenergic antagonists: R-enantiomers show increased selectivity for beta-2 receptors in ciliary process.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 1988;245:94&#8211;101.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.<Emphasis Type="Italic">J Pharm Pharm Sci</Emphasis>. 2001;4:185&#8211;200.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Sharif NA, Xu SX, Crider JY, McLaughlin M, Davis TL. Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes.<Emphasis Type="Italic">J Ocul Pharmacol Ther</Emphasis>. 2001;17:305&#8211;317.</td><td><a href=http://dx.doi.org/10.1089/108076801753162726>10.1089/108076801753162726</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Nandel FS, Dhaliwal RK, Singh B. Modeling, design, chiral aspects and role of para-substituents in aryloxypropranolamine based beta-blockers.<Emphasis Type="Italic">Indian J Biochem Biophys</Emphasis>. 1999;36:29&#8211;35.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR32</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Quigley</span> <span style='background:#DDDDDD'>H.</span></span></aug> How common is glaucoma <i>worldwide?Int Glaucoma Rev</i> [serial online]. 2002; Available at: <span style='background:#FF3300'>http://www.glaucom.com/Mettings/3-3/worldwide.php</span>. Accessed August 16, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR33</td><td>BibChapter</td><td>Moroi SE, Lichter PR. Ocular pharmacology. In: Hardman JG, Limbird LE, eds.<Emphasis Type="Italic">Goodman &amp; Gilman&#8217;s The Pharmacological Basis of Therapeutics</Emphasis>. New York, NY: McGraw-Hill; 1996:1619&#8211;1645.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Alward WL. Biomedicine: a new angle on ocular development.<Emphasis Type="Italic">Science</Emphasis>. 2003;299:1527&#8211;1528.</td><td><a href=http://dx.doi.org/10.1126/science.1082933>10.1126/science.1082933</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Radius RL, Diamond GR, Pollack IP, Langham ME. Timolol: a new drug for management of chronic simple glaucoma.<Emphasis Type="Italic">Arch Ophthalmol</Emphasis>. 1978;96:1003&#8211;1008.</td><td><a href=http://dx.doi.org/10.1001/archopht.1978.03910050527005>10.1001/archopht.1978.03910050527005</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Sugrue MF. New approaches to antiglaucoma therapy.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1997;40:2793&#8211;2809.</td><td><a href=http://dx.doi.org/10.1021/jm9608725>10.1021/jm9608725</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Stamper RL, Wigginton SA, Higginbotham EJ. Primary drug treatment for glaucoma: beta-blockers versus other medications.<Emphasis Type="Italic">Surv Ophthalmol</Emphasis>. 2002;47:63&#8211;73.</td><td><a href=http://dx.doi.org/10.1016/S0039-6257(01)00286-7>10.1016/S0039-6257(01)00286-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Taniguchi T, Kitazawa Y. The potential systemic effect of topically applied beta-blockers in glaucoma therapy.<Emphasis Type="Italic">Curr Opin Ophthalmol</Emphasis>. 1997;8:55&#8211;58.</td><td><a href=http://dx.doi.org/10.1097/00055735-199704000-00010>10.1097/00055735-199704000-00010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1999;128:301&#8211;309.</td><td><a href=http://dx.doi.org/10.1016/S0002-9394(99)00160-9>10.1016/S0002-9394(99)00160-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978&#8211;1985.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1986;102:606&#8211;611.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical &#946;-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol.<Emphasis Type="Italic">Arch Ophthalmol</Emphasis>. 1988;106:908&#8211;911.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1001/archopht.1988.01060140054023>10.1001/archopht.1988.01060140054023</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Fraunfelder FT, Meyer SM. Sexual dysfunction secondary to topical ophthalmic timolol.<Emphasis Type="Italic">JAMA</Emphasis>. 1985;253:3092&#8211;3093.</td><td><a href=http://dx.doi.org/10.1001/jama.253.21.3092>10.1001/jama.253.21.3092</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Sorensen SJ, Abel SR. Comparison of the ocular beta-blockers.<Emphasis Type="Italic">Ann Pharmacother</Emphasis>. 1996;30:43&#8211;54.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Schoene RB, Martin TR, Charan NB, French CL. Timolol-induced bronchospasm in asthmatic bronchitis.<Emphasis Type="Italic">JAMA</Emphasis>. 1981;245:1460&#8211;1461.</td><td><a href=http://dx.doi.org/10.1001/jama.245.14.1460>10.1001/jama.245.14.1460</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Van Buskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM, Drake MM. Betaxolol in patients with glaucoma and asthma.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1986;101:531&#8211;534.</td><td><a href=http://dx.doi.org/10.1016/0002-9394(86)90941-4>10.1016/0002-9394(86)90941-4</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1, VolumeID, ArticleTitle, Year</td><td>CrossRef</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol.<Emphasis Type="Italic">Am J Ophthalmol</Emphasis>. 1986;102:274&#8211;275.</td><td><a href=http://dx.doi.org/10.1016/0002-9394(86)90157-1>10.1016/0002-9394(86)90157-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Pfitzner KE, Moffat JG, Sulfoxide-carbodiimide reactions. I. A facile oxidation of alcohols.<Emphasis Type="Italic">J Am Chem Soc</Emphasis>. 1965;87:5661&#8211;5670.</td><td><a href=http://dx.doi.org/10.1021/ja00952a026>10.1021/ja00952a026</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Bodor N. The soft drug approach.<Emphasis Type="Italic">Chemtech</Emphasis>. 1984;14:28&#8211;38.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Bodor N, Buchwald P. Soft drug design: general principles and recent applications.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 2000;20:58&#8211;101.</td><td><a href=http://dx.doi.org/10.1002/(SICI)1098-1128(200001)20:1&lt;58::AID-MED3&gt;3.0.CO;2-X>10.1002/(SICI)1098-1128(200001)20:1&lt;58::AID-MED3&gt;3.0.CO;2-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibChapter</td><td>Bodor N. Designing safer ophthalmic drugs. In:<Emphasis Type="Italic">Trends in Medicinal Chemistry &#8217;88: Proceedings of the Xth International Symposium on Medicinal Chemistry</Emphasis>. Amsterdam, The Netherlands: Elsevier; 1989:145&#8211;164.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR51</td><td>BibChapter</td><td>Bodor N. The use of retrometabolic drug design concepts in ophthalmic drug discovery. In: Reddy IK, ed.<Emphasis Type="Italic">Ocular Therapeutics and Drug Delivery: A Multidisciplinary Approach</Emphasis>. Lancaster, PA: Technomic; 1996:335&#8211;361.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR52</td><td>BibBook</td><td>Albert A.<Emphasis Type="Italic">Selective Toxicity: The Physico-Chemical Basis of Therapy</Emphasis>. London, UK: Chapman and Hall; 1985.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-94-009-4846-4>10.1007/978-94-009-4846-4</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, ChapterTitle</td><td>CrossRef</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Gillette JR. Effects of induction of cytochrome P-450 enzymes on the concentration of foreign compounds and their metabolites and on the toxicological effects of these compounds.<Emphasis Type="Italic">Drug Metab Rev</Emphasis>. 1979;10:59&#8211;87.</td><td><a href=http://dx.doi.org/10.3109/03602537908993901>10.3109/03602537908993901</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54</td><td>BibChapter</td><td>Mannering GJ. Hepatic cytochrome P-450-linked drug-metabolizing systems. In: Testa B, Jenner P, eds.<Emphasis Type="Italic">Concepts in Drug Metabolism. Part B</Emphasis>. New York, NY: Marcel Dekker Inc; 1981:53&#8211;166.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Borg KO, Carlsson E, Hoffmann K-J, J&#246;nsson K-J, Thorin H, Wallin B. Metabolism of metoprolol-(<Superscript>3</Superscript>H) in man, the dog and the rat.<Emphasis Type="Italic">Acta Pharmacol Toxicol (Copenh)</Emphasis>. 1975;36:125&#8211;135.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1111/j.1600-0773.1975.tb03329.x>10.1111/j.1600-0773.1975.tb03329.x</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, VolumeID</td><td>CrossRef</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Regardh CG, Johnsson G. Clinical pharmacokinetics of metoprolol.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1980;5:557&#8211;569.</td><td><a href=http://dx.doi.org/10.2165/00003088-198005060-00004>10.2165/00003088-198005060-00004</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Benfield P, Clissold SP, Brogden RN. Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.<Emphasis Type="Italic">Durgs</Emphasis>. 1986;31:376&#8211;429.</td><td><a href=http://dx.doi.org/10.2165/00003495-198631050-00002>10.2165/00003495-198631050-00002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Bodor N, Oshiro Y, Loftsson T, Katovich M, Caldwell W. Soft drugs. 6. The application of the inactive metabolite approach for design of soft &#946;-blockers.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1984;1:120&#8211;125.</td><td><a href=http://dx.doi.org/10.1023/A:1016376003515>10.1023/A:1016376003515</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Bodor N, El-Koussi A, Kano M, Khalifa MM. Soft drugs. 7. &#946;-Blockers for systemic and ophthalmic use.<Emphasis Type="Italic">J Med Chem</Emphasis>. 1988;31:1651&#8211;1656.</td><td><a href=http://dx.doi.org/10.1021/jm00403a028>10.1021/jm00403a028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Bodor N, El-Koussi A. Novel &#8216;soft&#8217; &#946;-blockers as potential safe antiglaucoma agents.<Emphasis Type="Italic">Curr Eye Res</Emphasis>. 1988;7:369&#8211;374.</td><td><a href=http://dx.doi.org/10.3109/02713688809031786>10.3109/02713688809031786</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Polgar P, Bodor N. Cardiac electrophysiologic effects of adaprolol maleate, a new &#946;-blocker, in closed chest dogs.<Emphasis Type="Italic">Life Sci</Emphasis>. 1991;48:1519&#8211;1528.</td><td><a href=http://dx.doi.org/10.1016/0024-3205(91)90276-H>10.1016/0024-3205(91)90276-H</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Bodor N, El-Koussi A, Zuobi K, Kovacs P. Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma.<Emphasis Type="Italic">J Ocul Pharmacol Ther</Emphasis>. 1996;12:115&#8211;122.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1089/jop.1996.12.115>10.1089/jop.1996.12.115</a></td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR63</td><td>BibArticle</td><td>McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks.<Emphasis Type="Italic">Drug Saf</Emphasis>. 2002;25:33&#8211;55.</td><td><a href=http://dx.doi.org/10.2165/00002018-200225010-00004>10.2165/00002018-200225010-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Buchman AL. Side effects of corticosteroid therapy.<Emphasis Type="Italic">J Clin Gastroenterol</Emphasis>. 2001;33:289&#8211;294.</td><td><a href=http://dx.doi.org/10.1097/00004836-200110000-00006>10.1097/00004836-200110000-00006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Raizman M. Corticosteroid therapy of eye disease: fifty years later.<Emphasis Type="Italic">Arch Ophthalmol</Emphasis>. 1996;114:1000&#8211;1001.</td><td><a href=http://dx.doi.org/10.1001/archopht.1996.01100140208016>10.1001/archopht.1996.01100140208016</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, VolumeID, Year, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspectives from in vitro and lens culture studies.<Emphasis Type="Italic">Exp Eye Res</Emphasis>. 1997;65:507&#8211;516.</td><td><a href=http://dx.doi.org/10.1006/exer.1997.0359>10.1006/exer.1997.0359</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Heyns K, Koch W. &#220;ber die bildung eines aminozuckers aus<Emphasis Type="Italic">d</Emphasis>-fruktose und ammoniak.<Emphasis Type="Italic">Z Naturforsch [B]</Emphasis>. 1952;7B:486&#8211;488.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Bucala R, Fishman J, Cerami A. Formation of covalent adducts between cortisol and 16&#945;-hydroxyestrone and protein: possible role in the pathogenesis of cortisol toxicity and systemic lupus erythematosus.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1982;79:3320&#8211;3324.</td><td><a href=http://dx.doi.org/10.1073/pnas.79.10.3320>10.1073/pnas.79.10.3320</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Manabe S, Bucala R, Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts.<Emphasis Type="Italic">J Clin Invest</Emphasis>. 1984;74:1803&#8211;1810.</td><td><a href=http://dx.doi.org/10.1172/JCI111599>10.1172/JCI111599</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Bucala R, Gallati M, Manabe S, Cotlier E, Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts.<Emphasis Type="Italic">Exp Eye Res</Emphasis>. 1985;40:853&#8211;863.</td><td><a href=http://dx.doi.org/10.1016/0014-4835(85)90130-7>10.1016/0014-4835(85)90130-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Urban RC, Jr, Cotlier E. Corticosteroid-induced cataracts.<Emphasis Type="Italic">Surv Ophthalmol</Emphasis>. 1986;31:102&#8211;110.</td><td><a href=http://dx.doi.org/10.1016/0039-6257(86)90077-9>10.1016/0039-6257(86)90077-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation.<Emphasis Type="Italic">Bio Drugs</Emphasis>. 1998;10:329&#8211;339.</td><td><a href=http://dx.doi.org/10.2165/00063030-199810040-00007>10.2165/00063030-199810040-00007</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, Author_FamilyName_2, Year, ArticleTitle, VolumeID</td><td>CrossRef</td></tr><tr><td>CR73</td><td>BibArticle</td><td>Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2000;55:178&#8211;183.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR74</td><td>BibChapter</td><td>Bodor N, Buchwald P. Design and development of a soft corticosteroid, loteprednol etabonate. In: Schleimer RP, O&#8217;Byrne PM, Szefler SJ, Brattsand R, eds.<Emphasis Type="Italic">Inhaled Steroids in Asthma. Optimizing Effects in the Airways</Emphasis>. New York, NY: Marcel Dekker, 2002:541&#8211;564.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR75</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bodor</span> <span style='background:#DDDDDD'>N</span></span></aug>, <span style='background:#FFD9B3'>inventor</span>. <i>St&#233;ro&#239;ds doux exer&#231;ant une activit&#233; antiinflammatoire (Steroids having antiinflammatory activity)</i>. Belgian patent BE889,563 (Internat Classif C07J/A61K). November 3, 1981.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Bodor N, Varga M. Effect of a novel soft steroid on the wound healing of rabbit cornea.<Emphasis Type="Italic">Exp Eye Res</Emphasis>. 1990;50:183&#8211;187.</td><td><a href=http://dx.doi.org/10.1016/0014-4835(90)90229-N>10.1016/0014-4835(90)90229-N</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77</td><td>BibArticle</td><td>Druzgala P, Hochhaus G, Bodor N. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate.<Emphasis Type="Italic">J Steroid Biochem</Emphasis>. 1991;38:149&#8211;154.</td><td><a href=http://dx.doi.org/10.1016/0960-0760(91)90120-T>10.1016/0960-0760(91)90120-T</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78</td><td>BibArticle</td><td>Bodor N, Loftsson T, Wu W-M. Metabolism, distribution, and transdermal permeability of a soft corticosteroid, loteprednol etabonate.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1992;9:1275&#8211;1278.</td><td><a href=http://dx.doi.org/10.1023/A:1015849132396>10.1023/A:1015849132396</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Hochhaus G, Chen L-S, Ratka A, et al. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 1992;81:1210&#8211;1215.</td><td><a href=http://dx.doi.org/10.1002/jps.2600811217>10.1002/jps.2600811217</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80</td><td>BibArticle</td><td>Bodor N, Murakami T, Wu W-M. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats&#8212;for safer treatment of gastrointestinal inflammation.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1995;12:869&#8211;874.</td><td><a href=http://dx.doi.org/10.1023/A:1016213121069>10.1023/A:1016213121069</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Bodor N, Wu W-M, Murakami T, Engel S. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1995;12:875&#8211;879.</td><td><a href=http://dx.doi.org/10.1023/A:1016265105139>10.1023/A:1016265105139</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Monder C, Bradlow HL. Cortoic acids: explorations at the frontier of corticosteroid metabolism.<Emphasis Type="Italic">Recent Prog Horm Res</Emphasis>. 1980;36:345&#8211;400.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/B978-0-12-571136-4.50016-4>10.1016/B978-0-12-571136-4.50016-4</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR83</td><td>BibChapter</td><td>Bodor N. Novel approaches for the design of membrane transport properties of drugs. In: Roche EB, ed.<Emphasis Type="Italic">Design of Biopharmaceutical Properties Through Prodrugs and Analogs</Emphasis>. Washington, DC: Academy of Pharmaceutical Sciences; 1977:98&#8211;135.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR84</td><td>BibArticle</td><td>Bodor N. Designing safer drugs based on the soft drug approach.<Emphasis Type="Italic">Trends Pharmacol Sci</Emphasis>. 1982;3:53&#8211;56.</td><td><a href=http://dx.doi.org/10.1016/0165-6147(82)91008-2>10.1016/0165-6147(82)91008-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR85</td><td>BibChapter</td><td>Bodor N. Soft drugs: strategies for design of safer drugs.<Emphasis Type="Italic">Metabolisme et Conception Medicaments: Quo Vadis? Proceedings of Symposium at Montpellier, France; November 26&#8211;27, 1981</Emphasis>; Montpellier, France, CLIN MIDY; 1983. 217&#8211;251.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Druzgala P, Bodor N. Regioselective O-alkylation of cortienic acid and synthesis of a new class of glucocorticoids containing a 17&#945;-alkoxy, a 17&#945;-(1&#8217;-alkoxyethyloxy), a 17&#945;-alkoxymethyloxy, or a 17&#945;-methylthiomethyloxy function.<Emphasis Type="Italic">Steroids</Emphasis>. 1991;56:490&#8211;494.</td><td><a href=http://dx.doi.org/10.1016/0039-128X(91)90008-J>10.1016/0039-128X(91)90008-J</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibChapter</td><td>Bodor N. The application of soft drug approaches to the design of safer corticosteroids. In: Christophers E, Kligman AM, Sch&#246;pf E, Stoughton RB, eds.<Emphasis Type="Italic">Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs</Emphasis>. New York, NY: Raven Press Ltd; 1988:13&#8211;25.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Buchwald P, Bodor N. Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2004;59:396&#8211;404.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Buchwald P. General linearized biexponential model for QSAR data showing bilinear-type distribution.<Emphasis Type="Italic">J Pharm Sci</Emphasis>. 2005;94:2355&#8211;2379.</td><td><a href=http://dx.doi.org/10.1002/jps.20438>10.1002/jps.20438</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Druzgala P, Wu W-M, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes.<Emphasis Type="Italic">Curr Eye Res</Emphasis>. 1991;10:933&#8211;937.</td><td><a href=http://dx.doi.org/10.3109/02713689109020329>10.3109/02713689109020329</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Bodor N, Bodor N, Wu W-M. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.<Emphasis Type="Italic">Curr Eye Res</Emphasis>. 1992;11:525&#8211;530.</td><td><a href=http://dx.doi.org/10.3109/02713689209001808>10.3109/02713689209001808</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate.<Emphasis Type="Italic">J Glaucoma</Emphasis>. 1998;7:266&#8211;269.</td><td><a href=http://dx.doi.org/10.1097/00061198-199808000-00009>10.1097/00061198-199808000-00009</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, VolumeID, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Howes J, Novack GD. Failure to detect systemic levels and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration.<Emphasis Type="Italic">J Ocul Pharmacol Ther</Emphasis>. 1998;14:153&#8211;158.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1089/jop.1998.14.153>10.1089/jop.1998.14.153</a></td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR94</td><td>BibUnstructured</td><td><span style='background:#FFD9B3'>Lotemax (Loteprednol Etabonate Ophthalmic Suspension 0.5%) [product monograph]</span>. <span style='background:#C0FFC0'>Rochester, NY</span>: <span style='background:#FFFF49'>Bausch & Lomb Pharmaceuticals</span>. <span style='background:#66FF66'>1998</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR95</td><td>BibArticle</td><td>Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Longterm safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.<Emphasis Type="Italic">Eye Contact Lens</Emphasis>. 2004;30:10&#8211;13.</td><td><a href=http://dx.doi.org/10.1097/01.ICL.0000092071.82938.46>10.1097/01.ICL.0000092071.82938.46</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Szelenyi I, Hermann R, Petzold U, Pahl A, Hochhaus G. Possibilities in improvement of glucocorticoid treatments in asthma with special reference to loteprednol etabonate.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2004;59:409&#8211;411.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Szelenyi I, Hochhaus G, Heer S, et al. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways.<Emphasis Type="Italic">Drugs Today (Barc)</Emphasis>. 2000;36:313&#8211;320.</td><td><a href=http://dx.doi.org/10.1358/dot.2000.36.5.575043>10.1358/dot.2000.36.5.575043</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, VolumeID, Author_FamilyName_1, JournalTitle, FirstPage, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR98</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bodor</span> <span style='background:#DDDDDD'>N</span></span></aug>, <span style='background:#FFD9B3'>inventor</span>. <i>Androstene derivatives</i>. US patent 5 981 517. November 9, 1999.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR99</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Barton</span> <span style='background:#DDDDDD'>P</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Laws</span> <span style='background:#DDDDDD'>AP</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Page</span> <span style='background:#DDDDDD'>MI</span></span></aug>. <span style='background:#FFD9B3'>Structure-activity relationships in the esterase-catalysed hydrolysis and transesterification of esters and lactones</span>. <i>J Chem Soc, Perkin Trans</i> <i>2</i>. <span style='background:#66FF66'>1994</span>; <span style='background:#D279FF'>2021&#8211;2029</span>.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1039/P29940002021>10.1039/P29940002021</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_1, Author_FamilyName_2, FirstPage</td><td>CrossRef</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Mikl&#243;s A, Magyar Z, Kiss &#201;, et al. 28-Day oral toxicity study with soft corticosteroid BNP-166 in rats and dogs, followed by a 14-day recovery period.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2002;57:142&#8211;146.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Kurucz I, T&#243;th S, N&#233;meth K, et al. Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166).<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2003;307:83&#8211;92.</td><td><a href=http://dx.doi.org/10.1124/jpet.103.053652>10.1124/jpet.103.053652</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR102</td><td>BibArticle</td><td>Kurucz I, N&#233;meth K, M&#233;sz&#225;ros S, et al. Anti-inflammatory effect and soft properties of etiprednol dicloacetate (BNP-166), a new, antiasthmatic steroid.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2004;59:412&#8211;416.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR103</td><td>BibArticle</td><td>Jaffuel D, Demoly P, Gougat C, et al. Transcriptional potencies of inhaled glucocorticoids.<Emphasis Type="Italic">Am J Respir Crit Care Med</Emphasis>. 2000;162:57&#8211;63.</td><td><a href=http://dx.doi.org/10.1164/ajrccm.162.1.9901006>10.1164/ajrccm.162.1.9901006</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, ArticleTitle, Year, Author_FamilyName_2, JournalTitle, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR104</td><td>BibArticle</td><td>Bhalay G, Sandham DA. Recent advances in corticosteroids for the treatment of asthma.<Emphasis Type="Italic">Curr Opin Investig Drugs</Emphasis>. 2002;3:1149&#8211;1156.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>